Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716077 · ClinicalTrials.gov registry record · NA
Early FDG PET in Melanoma
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02716077 is a NA study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants.
The verdict
NCT02716077, a NA study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.
Interventions
- RADIATION FDG PET/CT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716077
The ClinicalTrials.gov registry entry for NCT02716077 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FDG PET/CT imaging is the first listed.
NCT02716077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02716077 about?
NCT02716077 is a clinical study titled "Early FDG PET in Melanoma". Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.
What is the current status of trial NCT02716077?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2016-03. Estimated completion is 2021-03.
What interventions are being tested in trial NCT02716077?
The interventions under investigation include: FDG PET/CT imaging (RADIATION).
Who is sponsoring clinical trial NCT02716077?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.